Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

Blood

Volumn 125, Issue 24, 2015, Pages 3711-3719

  Chalandon, Yves ^a   Thomas, Xavier ^c   Hayette, Sandrine ^c   Cayuela, Jean Michel ^d   Abbal, Claire ^e   Huguet, Françoise ^f   Raffoux, Emmanuel ^d   Leguay, Thibaut ^g   Rousselot, Philippe ^h   Lepretre, Stéphane ⁱ   Escoffre Barbe, Martine ^j   Maury, Sébastien ^k   Berthon, Céline ^l   Tavernier, Emmanuelle ^m   Lambert, Jean François ^b,e   Lafage Pochitaloff, Marina ⁿ   Lhéritier, Véronique ^o   Chevret, Sylvie ^d   Ifrah, Norbert ^p   Dombret, Hervé ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c Hospices Civils de Lyon   (Switzerland)

^d SAINT LOUIS HOSPITAL   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Institut Universitaire de Cancérologie   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j Service ORL   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m Lucien Neuwirth Cancer Institute   (France)

ⁿ TIMONE HOSPITAL   (France)

^o Group for Research on Adult Acute Lymphoblastic Leukemia Coordination Office   (France)

^p ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FILGRASTIM; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PEGFILGRASTIM; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADOLESCENT; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930352842     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-627935     Document Type: Article

References (34)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.
2. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E; GMALL study group. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918-919.
3. Picard C, Hayette S, Bilhou-Nabera C, et al. Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. Leukemia. 2006;20(12):2178-2181.
4. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998;40(3):119-128.
5. Dombret H, Gabert J, Boiron JM, et al; Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-2366.
6. Bassan R, Rohatiner AZ, Lerede T, et al. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Hematol J. 2000;1(4):226-234.
7. Gleissner B, Gökbuget N, Bartram CR, et al German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536-1543.
8. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ ECOG2993. Blood. 2009;113(19):4489-4496.
9. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396-4407.
10. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005;19(9):1509-1516.
11. de Labarthe A, Rousselot P, Huguet-Rigal F, et al Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomepositive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408-1413.
12. Towatari M, Yanada M, Usui N, et al Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104(12):3507-3512.
13. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood. 2006;108(5):1469-1477.
14. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150-155.
15. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104(6):1624-1630.
16. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447-1454.
17. Kaplan EL, Meier O. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
18. Cox DR. Regression models and life tables. JR Stat Soc B. 1972;34:187-220.
19. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81-86.
20. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44.
21. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100-1120.
22. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
23. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
24. Schultz KR, Carroll A, Heerema NA, et al Children's Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosomepositive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-1471.
25. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843-850.
26. Yanada M, Naoe T. Imatinib combined chemotherapy for Philadelphia chromosomepositive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma. 2006;47(9):1747-1753.
27. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214-1221.
28. Beldjord K, Chevret S, Asnafi V, et al Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739-3749.
29. Dhédin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486-2496.
30. Pfeifer H, Wassmann B, Bethge W, et al GMALL Study Group. Randomized comparison of prophylactic and minimal residual diseasetriggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254-1262.
31. Topp MS, Gökbuget N, Zugmaier G, et al. Longterm follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185-5187.
32. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, singlearm, phase 2 study. Lancet Oncol. 2015;16(1): 57-66.
33. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
34. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.